Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/112325
Título: JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia
Autores/as: Aranda Tavío, Haidée Magdalena 
Recio Cruz, Carlota Pilar 
Martín-Acosta, Pedro
Guerra Rodríguez, Miguel Alfonso 
Brito Casillas, Yeray 
Blanco, Rosa
Junco, Vanessa
León, Javier
Montero, Juan Carlos
Gandullo-Sánchez, Lucía
McNaughton-Smith, Grant
Zapata, Juan Manuel
Pandiella, Atanasio
Amesty, Angel
Estévez-Braun, Ana
Fernández Pérez, Leandro Fco 
Guerra Hernández, Carlos Borja 
Clasificación UNESCO: 32 Ciencias médicas
3209 Farmacología
320101 Oncología
Palabras clave: Chronic myelogenous leukemia
BCR-ABL1
Synergism
Imatinib resistance
Fecha de publicación: 2021
Proyectos: Desarrollo Preclínico de Nuevas Estructuras Bioactivas Moduladoras de Las Actividades Oncogénicas de Stat3/5 O de Los Receptores de Estrógenos 
Cribado Farmacológico de Librerías Químicas y Desarrollo Preclínico de Nuevas Entidades Moduladoras de Los Oncogenes Stat3/5 y Yap1, y Del Receptor de Estrógenos (Serm) 
Aplicación de Una Plataforma de Bioensayos en El Cribado de Bibliotecas Químicas Inspiradas en la Biodiversidad: Identificación y Desarrollo de Moléculas Con Interés Biomédico en Oncología. 
Publicación seriada: Biomedicine and Pharmacotherapy 
Resumen: Chronic myelogenous leukemia (CML) is a hematological malignancy that highly depends on the BCR-ABL1/STAT5 signaling pathway for cell survival. First-line treatments for CML consist of tyrosine kinase inhibitors that efficiently target BCR-ABL1 activity. However, drug resistance and intolerance are still therapeutic limitations in Ph+ cells. Therefore, the development of new anti-CML drugs that exhibit alternative mechanisms to overcome these limitations is a desirable goal. In this work, the antitumoral activity of JKST6, a naphthoquinone-pyrone hybrid, was assessed in imatinib-sensitive and imatinib-resistant human CML cells. Live-cell imaging analysis revealed JKST6 potent antiproliferative activity in 2D and 3D CML cultures. JKST6 provoked cell increase in the subG1 phase along with a reduction in the G0/G1 phase and altered the expression of key proteins involved in the control of mitosis and DNA damage. Rapid increases in Annexin V staining and activation/cleavage of caspases 8, 9 and 3 were observed after JKST6 treatment in CML cells. Of interest, JKST6 inhibited BCR-ABL1/STAT5 signaling through oncokinase downregulation that was preceded by rapid polyubiquitination. In addition, JKST6 caused a transient increase in JNK and AKT phosphorylation, whereas the phosphorylation of P38-MAPK and Src was reduced. Combinatory treatment unveiled synergistic effects between imatinib and JKST6. Notably, JKST6 maintained its antitumor efficacy in BCR-ABL1-T315I-positive cells and CML cells that overexpress BCR-ABL and even restored imatinib efficacy after a short exposure time. These findings, together with the observed low toxicity of JKST6, reveal a novel multikinase modulator that might overcome the limitations of BCR-ABL1 inhibitors in CML therapy.
URI: http://hdl.handle.net/10553/112325
ISSN: 0753-3322
DOI: 10.1016/j.biopha.2021.112330
Fuente: Biomedicine and Pharmacotherapy [ISSN 0753-3322], v. 144, 112330, (Diciembre 2021)
Colección:Artículos
Adobe PDF (10,82 MB)
Vista completa

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.